NCT07318389

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Detailed description

Primary Objectives * To determine differences in PFS based on differential response markers in paired tissue biopsies (Part I). * To improve progression-free survival with novel intervention strategies (Part II) Secondary Objectives * To collect serial tissue and blood biomarkers and efficacy data associated with standard of care or investigational therapy across multiple lines of therapy. * To determine the overall response rate (ORR), and overall survival (OS) based on the presence of specific biomarkers or adaptive interventions.

Conditions

• Dynamic Tumor Resistance
• Metastatic Colorectal Cancer

Interventions

Type	Name	Description
OTHER	SOC (Standard of care)	Blood draws, biopsies, samples and MRI.
DRUG	Bevacizumab	Given by IV
DRUG	Cetuximab	Given by Iv
DRUG	Panitumumab	Given by Iv
DRUG	FOLFIRI	Given by Iv
DRUG	FOLFOX	Given by Iv
DRUG	Encorafenib	Given by po
DRUG	Adagrasib	Given by Po
DRUG	Trifluridine/tipiracil (TAS-102)	Given by po
DRUG	Trastuzumab deruxtecan	Given by IV
DRUG	Tucatinib	Given by po
DRUG	Sotorasib	Given by po

Timeline

• Start date: 2026-06-10
• Primary completion: 2027-11-14
• Completion: 2029-11-14
• First posted: 2026-01-06
• Last updated: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study